Adolor Corporation Announces Management Appointments

Adolor Corporation Announces Management Appointments
EXTON, Pa., Jan 14, 2010 (BUSINESS WIRE) -- Adolor Corporation (NasdaqGM: ADLR) today announced the following promotions:
Michael D. Adelman has been promoted to the position of Vice President, Marketing and Sales. Mr. Adelman, 39, joined Adolor in late 2008 as Senior Director, Marketing where he directed the Company's marketing activities for ENTEREG(R) (alvimopan). Prior to joining Adolor, Mr. Adelman held positions of increasing responsibility at AstraZeneca Pharmaceuticals, LP in Product Marketing and Sales, including serving on the Marketing Strategy Leadership Team.

David P. Geoghegan has been promoted to Vice President, Manufacturing. Mr. Geoghegan will continue to report to George R. Maurer, Senior Vice President, Manufacturing and Pharmaceutical Technologies. Mr. Geoghegan, 44, joined Adolor in 2004 as Senior Director, Manufacturing Process Quality where he has led the quality control of Adolor's commercial supply chain. For over 20 years, Mr. Geoghegan has held technical, quality and management positions in the biopharmaceutical industry. Prior to joining Adolor, he worked most recently at MedImmune, Inc. as Director, QA Corporate Compliance.

Kevin Darryl White has been promoted to Vice President, Regulatory Affairs. Mr. White, 52, joined Adolor in 2008 as Senior Director, Regulatory Affairs where he managed the regulatory strategy for the Company's commercial product and development programs. For 30 years, Mr. White has held positions of increasing responsibilities in both the pharmaceutical industry and the U. S. Food and Drug Administration. He most recently was at Palatin Technologies as Director, Regulatory Affairs.

"We are fortunate to have an extremely talented leadership team at Adolor and I am pleased to be able to appoint Mike, David and KD to these management positions," said Michael R. Dougherty, President and Chief Executive Officer. "Their collective dedication and expertise will continue to drive our commercial operations and pipeline development."

About Adolor Corporation

Adolor Corporation is a biopharmaceutical company specializing in the discovery, development and commercialization of novel prescription pain management products.

Adolor's first approved product in the United States is ENTEREG(R) (alvimopan), which is indicated to accelerate the time to upper and lower gastrointestinal recovery following partial large or small bowel resection surgery with primary anastomosis. ENTEREG is available for short-term use in hospitals registered under the E.A.S.E.(TM) Program. For more information on ENTEREG, including its full prescribing information, visit www.ENTEREG.com. In collaboration with GlaxoSmithKline (GSK), the Company launched ENTEREG in mid-2008.

The Company's research and development pipeline includes: two novel delta opioid receptor agonists, currently in mid-stage clinical development in collaboration with Pfizer Inc. for chronic pain; two opioid receptor antagonists, ADL7445 and ADL5945, entering clinical development for opioid bowel dysfunction (OBD); and several opioid and non-opioid discovery programs.

For more information, visit www.adolor.com.

Forward-Looking Statements

This press release, and oral statements made with respect to information contained in this release, may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide Adolor's current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs; development of potential pharmaceutical products; interpretation of clinical results; prospects for regulatory approval; market prospects for ENTEREG; and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning or that otherwise express contingencies, goals, targets or future development. These statements are based upon management's current expectations and are subject to risks and uncertainties, known and unknown, that could cause actual results and developments to differ materially from those expressed or implied in such statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries, as well as more specific risks and uncertainties facing Adolor such as those set forth in its reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Adolor urges you to carefully review and consider the disclosures found in its filings which are available at http://www.sec.gov and from Adolor at www.adolor.com. Given the uncertainties affecting pharmaceutical companies such as Adolor, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Adolor undertakes no obligation to publicly update or revise the statements made herein or the risk factors that may relate thereto whether as a result of new information, future events, or otherwise, except as may be required by law.

This press release is available on the website http://www.adolor.com.

 

SOURCE: Adolor Corporation

Adolor CorporationLizanne WentzCorporate Communications484-595-1500

 

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.